QX002N demonstrated favorable safety and preliminary efficacy in active ankylosing spondylitis: phase 1b study results
Deucravacitinib demonstrated significant improvements in patient-reported outcomes in phase II SLE trial
Subcutaneous Tocilizumab, Alone or with Methotrexate, Demonstrated Superior Efficacy Over Methotrexate Monotherapy in Chinese RA Patients
Deucravacitinib demonstrates broad minimal disease activity component improvements in psoriatic arthritis: Phase 2 trial results
Anifrolumab Shows Durable Benefits in Achieving LLDAS and Remission in SLE: TULIP and Extension Trial Outcomes
